Gedivumab

Drug Profile

Gedivumab

Alternative Names: MHAA-4549A; RG 7745; RO 6876802

Latest Information Update: 08 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genentech
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Influenza virus haemagglutinin glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Influenza A virus infections

Most Recent Events

  • 21 Apr 2018 Efficacy and adverse events data from a phase IIb trial in Influenza-A virus infections presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2018)
  • 13 Nov 2017 Genentech completes a phase II trial in Influenza-A virus infections (Monotherapy) in USA, Canada, South Korea, New Zealand, South Africa, Spain, and United Kingdom (IV) (NCT02623322)
  • 23 May 2017 Genentech completes a phase II trial in Influenza-A virus infections (Combination therapy) in Belgium, Brazil, Bulgaria, Canada, Chile, Czech Republic, France, Germany, Hong Kong, Hungary, Italy, Netherlands, New Zealand, Peru, Poland, South Korea, Spain, Sweden and United Kingdom, Taiwan, Ukraine, Russia, South Africa, Mexico, Israel (NCT02293863)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top